Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,021Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,476Price:$1.90
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,021Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Kerr DouglasOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,021Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Kerr DouglasOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,476Price:$1.90
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Kerr DouglasOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,021Price:--
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,694Price:--
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,437Price:--
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,320Price:$1.91
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:6,694Price:--
Filings by filing date
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,021Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,476Price:$1.90
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,021Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Kerr DouglasOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,021Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Kerr DouglasOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,476Price:$1.90
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Kerr DouglasOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,021Price:--
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,694Price:--
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,437Price:--
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,320Price:$1.91
-
Jan 15, 2024 (filed on Jan 17, 2024)Insider Name:Zimmermann TracyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:6,694Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 301 BINNEY STREET CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://generationbio.com |
IR: | See website |
Key People | ||
Cameron Geoffrey Mcdonough President, Chief Executive Officer, Director | Matthew Norkunas Chief Financial Officer | Antoinette Paone Chief Operating Officer |
Matthew Stanton Chief Scientific Officer | Phillip Samayoa Chief Strategy Officer | Yalonda Howze Chief Legal Officer, Secretary |
Business Overview |
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Generation Bio Co revenues increased from $0K to $5.9M. Net loss decreased 7% to $126.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income - Non Bank increase from $4.5M to $12M (income), Stock-based Compensation in R&D decrease of 7% to $11.5M (expense). |
Employees: | 174 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $5.90M as of Dec 31, 2023 |
EBITDA (TTM): | -$133.30M as of Dec 31, 2023 |
Net annual income (TTM): | -$126.61M as of Dec 31, 2023 |
Free cash flow (TTM): | -$60.14M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 66,477,111 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |